Finding an effective medication for patients with major depressive disorder is notoriously difficult, with 70% of patients failing to respond to the first drug prescribed and 30% not responding to the first four medications. Complicating matters, genetic mutations can increase psychotropic drug-related adverse events, including hospitalizations. A recent study indicates Myriad Genetics Inc.’s Genesight test can help minimize the risk of these negative events, with a reduction of nearly 40% in psychiatric-related hospitalizations and prescription of medications with significant gene-drug interactions.
New York-based Viewmind Inc. has applied for patent protection of methods and systems for detecting neurological disorders and/or measuring, fine-motor skills, processing speed, decision making, and cognitive processes by measuring eye movements, oculomotor features and pupil behavior.
Researchers from the Weizmann Institute of Science in Rehovot, Israel, are seeking – through the university’s commercial arm, Yeda Research and Development Co. Ltd. – to gain patent protection for methods and systems for detecting and treating attention deficit hyperactivity disorder (ADHD) that are based on nasal respiration parameters.
ABVC Biopharma Inc. entered a multiyear, global licensing agreement for its CNS drugs to treat major depressive disorder and attention deficit hyperactivity disorder. The license deal with Aibtl Biopharma Inc. would cover clinical trial, registration, manufacturing, supply and distribution rights. The products were valued at $667 million by a third party, according to ABVC.
3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD).
Otsuka Pharmaceutical Co. Ltd. has synthesized hydrogenated quinoxalines acting as serotonin and/or norepinephrine and/or dopamine reuptake inhibitors reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD).
ABVC Biopharma Inc is headquartered in San Francisco but it has its roots in Taiwan where it is digging into traditional medicine and validating it for the modern world. “There are a number of drugs that can’t be synthesized in the lab,” ABVC CEO Howard Doong told BioWorld, so he is going back to the original source of traditional Chinese medicines to validate them using traditional drug development models.
ABVC Biopharma Inc is headquartered in San Francisco but it has its roots in Taiwan where it is digging into traditional medicine and validating it for the modern world. “There are a number of drugs that can’t be synthesized in the lab,” ABVC CEO Howard Doong told BioWorld, so he is going back to the original source of traditional Chinese medicines to validate them using traditional drug development models.
C2orf82, also known as small novel rich in cartilage (SNORC), is a gene located on chromosome 2 that is known to play a role in chondrocyte maturation.